ARTICLE IN PRESS



FIG E1. Preventive and therapeutic effects of UA on allergic asthma. **A** and **C**, Schematic diagram of experimental protocol for the UA preventive model used in Fig 3, *A-D* (Fig E1, *A*), or the UA therapeutic model used in Fig 3, *E-H* (Fig E1, *C*). **B** and **D**, Lymphoid cells from mediastinal lymph nodes were restimulated with OVA, and production of IFN- γ , IL-4, IL-5, and IL-17A in culture media was determined. Data are representative of 3 independent experiments. The graph shows means ± SEMs. **P* < .05, ***P* < .01, and ****P* < .001.

ARTICLE IN PRESS



FIG E2. Effects of UA on a chronic asthma model. **A** and **E**, Schematic diagrams of experimental protocol for the chronic model using PAO/OVA (Fig E2, *B-D*) and OVA-alum (Fig E2, *F-H*), respectively. **B**, **C**, **F**, and **G**, Frequencies (Fig E2, *B* and *F*) and absolute numbers (Fig E2, *C* and *G*) of BAL fluid CD4⁺ T-cell subsets. **D** and **H**, Absolute numbers of total cells, macrophages (*mac*), eosinophils (*eo*), neutrophils (*neu*), and lymphocytes (*lym*) in BAL fluid. The graph shows means \pm SEMs. **P* < .05, ***P* < .01, and ****P* < .001.



FIG E3. Representative FACS plot of BAL CD4⁺ T cells of mice in Fig 1. BAL fluid cells were gated on CD45.2⁺TCR β ⁺CD4⁺ cells. Data are representative of 2 independent experiments. *WT*, Wild-type.



FIG E4. Plasticity and stability of $T_H 17$ cells during allergic asthma. **A**, Intracellular staining of IL-17A and other cytokines. Expression of indicated cytokines in lung enhanced YFP⁻ or enhanced YFP⁻ CD4⁺ T cells is shown. **B** and **C**, Naive CD4⁺CD25⁻CD62L^{high}CD44^{low} T cells from *ll17f^{tp}*×OT-II mice were stimulated under $T_H 17$ conditions, and RFP⁺ cells were FACS sorted (Fig E4, *B*) and transferred into B6.SJL congenic mice (CD45.1⁺) before challenging the recipients with allergens. Frequencies of BAL fluid CD4⁺ T-cell subsets were analyzed by using flow cytometry (Fig E4, *C*). Data are representative of 2 independent experiments (n = 3-4 per experiment).



FIG E5. SR2211, another ROR_Yt inhibitor, negatively regulates differentiation of human T_H2 cells. **A**, Representative FACS plot for *in vitro* T_H17 differentiation and percentage changes in IL-17⁺ROR_Yt⁺ T cells. **B**, Representative FACS plot for *in vitro* T_H2 differentiation and percentage change in IL-4–producing T cells. Each *symbol* represents an individual donor.